tetrahydroquinoline-sulfonamide substituted compounds, their preparation and use as medicaments.

A tetrahydro-quinoline-sulfonamide of general formula (I) ** ** Formula wherein R1, R2 and R3 independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated may be substituted with 1, 2 or 3 substituent (s) selected (s) independently from the group consisting of F, Cl, Br, -OH, C 1-6 aliphatic radical -CH3, -O-C2H5, -CN and -NRaRb, wherein Ra and Rb independently of one another, each represent a hydrogen atom; or an aliphatic radical C1-6 linear or branched, saturated or unsaturated, unsubstituted or at least monosubstituted; or Ra and Rb together with the bridging nitrogen atom form a saturated or unsaturated C3-9 heterocycloaliphatic radical, unsubstituted or at least monosubstituted, optionally containing at least one additional heteroatom as a ring member, which may be fused with a ring system mono- or bicyclic unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic; or Ra and Rb together with the bridging nitrogen atom form an at least monosubstituted heteroaryl radical C5-14 unsubstituted or optionally containing at least one additional heteroatom as a ring member, which may be condensed with a mono- or bicyclic ring unsubstituted or at least monosubstituted, saturated, unsaturated or aromatic; with the proviso that at least one of R1, R2 and R3 is a C1-6 alkyl group optionally substituted with 1, 2 or 3 substituent (s) as defined above; R4, R5 and R6, independent of one another, each represent a hydrogen atom or a halogen atom; R7 represents a hydrogen atom; or an aliphatic radical C1-6 linear or branched, saturated or unsaturated may be substituted with 1, 2 or 3 substituent (s) independently selected from the group consisting of F, -OH, O- CH3 and -O-C2H5; and R8 represents an alkyl radical -O-aryl or 5- to 14 members, which may be substituted with 1, 2 or 3 substituent (s) selected (s) independently from the group consisting of C1-5 alkyl, C1-5 , -SC 1-5 alkyl, -C (= O) -OH, -C (= O) -O-C1-5alkyl, -OC (= O) -C1-5-alkyl, F, Cl, Br, I, -CN, -CF3, -OCF3, -SCF3, -OH, -SH, -NH2, -NH (C1-5 alkyl), -N (C1-5 alkyl) 2, -NH-C (= O) -C C1-5, -N (C1-5 alkyl) -C (= O) -C1-5-alkyl, -NO2, -CHO, CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH (C1-5 alkyl), -C (= O) -N (C1-5 alkyl) 2, -S (= O) 2-C1-5 alkyl, -S (= O) 2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy, benzyloxy and benzyl, and which may be bonded via a C1-6 alkylene group, C2-6 alkenylene or C2-6 alkynylene linear or branched, containing heteroaryl radical 1, 2 or 3 heteroatom (s) (s) selected independently from N, O, and S as ring members; optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a physiologically acceptable salt, isomer , prodrug or solvate thereof.